a:5:{s:8:"template";s:5073:" {{ keyword }}
{{ text }}
";s:4:"text";s:8297:"ENDPOINTS by John Carroll & team — all the news at 11:30a ET, EARLY EDITIONby Arsalan Arif — skimmable links and news at 7:15a ET, New Dewpoint Therapeutics CEO Ameet Nathwani (Sanofi), L to R: Jeroen Bekaert, Ivan Dimov and Nate Fernhoff, Orca Bio (Orca), by Arsalan Arif — skimmable links and news at 7:15a ET. Biotechs, in­clud­ing those rel­a­tive­ly fresh off launch, have been go­ing pub­lic at a fren­zy since the pan­dem­ic be­gan. They li­censed 15 gene ther­a­pies in epilep­sy, neu­rode­vel­op­ment and neu­rode­gen­er­a­tive dis­or­ders, with an op­tion to li­cense 4 more. Is an IPO next? In­vestors have showed a will­ing­ness to put up­wards of $200 mil­lion to com­pa­nies that have yet to bring a drug in­to the clin­ic. But Jeroen Bekaert, Ivan Dimov and Nate Fernhoff saw potential there. Now, CEO Sandra Glucksmann is following up with a $57.6 million Series B round to steer the Cambridge, MA-based biotech in a slightly different direction. (AVXS) raised $86 million in an IPO on Thursday, February 11th 2016. Risks include a novel technology, early stage, and intense competition. A few weeks ago Kite and Allogene founder Arie Belldegrun jumped into the expanded syndicate for a Boston-based biotech called Dewpoint Therapeutics — a Polaris-birthed venture that’s styled itself as a drug development pioneer out to craft a major pipeline. We suggest investors consider an allocation. If you're already an Endpoints subscriber, enter your email below for a magic link that lets you sign in quickly without using a password. And the com­pa­ny said that it hopes to even­tu­al­ly con­struct its own com­mer­cial scale pro­duc­tion site in Dal­las – a prospect that per­haps could come soon­er rather than lat­er. Orca, one of this year’s Endpoints 11 startups, was founded by three entrepreneurs who were intrigued by Irv Weissman’s cell purification work while studying at Stanford. But it had already cleared another randomized controlled trial and the agency determined the benefits at a time of growing drug resistance outweighed the risk. Novo Seeds’ Jeroen Bakker thinks he’s found the next kinases. Please note this link is one-time use only and is valid for only 24 hours. Based in Bannockburn, Illinois, AveXis (NASDAQ: AVXS) is a clinical-stage gene therapy company that is developing novel treatments for patients suffering from rare, Long/Short Equity, Special Situations, Momentum, event-driven. The biotech would take a port­fo­lio ap­proach to gene ther­a­py, akin to the one pur­sued by Bridge­Bio (where Ses­sion had been CBO of gene ther­a­py). Illinois-based AveXis is a clinical-stage gene therapy company, developing novel treatments for patients suffering from rare neurological genetic diseases. Taysha launched in April as the brain­child of for­mer AveX­is CEO Sean Nolan and for­mer AveX­is cor­po­rate strat­e­gy chief RA Ses­sion II, who now serve as Taysha’s chair­man and CEO, re­spec­tive­ly. Illinois-based AveXis is a clinical-stage gene therapy company, developing novel treatments for patients suffering from rare neurological genetic diseases. As it turned out, Versant Ventures was also eyeing that very same drug out of Germany: PSMA-617, a radioligand therapeutic for castration-resistant prostate cancer. And the biotech is de­clin­ing all in­ter­view re­quests on the news, the kind of broad si­lence that can in­di­cate an IPO is in the pipeline. A few months after its last big catch — a $192 million Series D and rare unicorn status — Orca Bio has reeled in the FDA’s regenerative medicine advanced therapy (RMAT) designation for its experimental cell therapy to treat blood stem cell transplant patients. When they launched, Taysha said they planned to clin­i­cal stud­ies on a gene ther­a­py for Tay-Sachs dis­ease and then file three more INDs in 2021. Last October, the FDA OK’d a semi-controversial new antibiotic from Shionogi. “We actually put a term sheet out on that asset because we just thought the efficacy data were so profound there,” managing director Jerel Davis told Endpoints News, referring to a drug that registered a progression-free survival rate of 7.6 months among PSMA-positive patients, with one cohort hitting an overall survival rate of 13.5 months. “Since the introduction of Gleevec, it’s always been about kinases,” Bakker told Endpoints News, referring to the best-selling Novartis drug, first approved in 2001. The company issued 4,300,000 shares at $19.00-$21.00 per share. The early stage, European VC firm announced yesterday they led a $9 million seed round for Rappta Therapeutics, a Finnish biotech developing inhibitors for an enzyme called PP2A — protein phosphatase 2 — that Bakker thinks now hold the same kind of drug targeting potential as kinases did two decades ago for cancer. Gene ther­a­py tri­als, of course, can cost a fair bit of cash. But underneath those headlines came another piece of news: a grand jury subpoena. Three months ago, they launched Taysha with $30 mil­lion in Se­ries A fund­ing and a pipeline of gene ther­a­pies out of UT South­west­ern. Three months ago, they launched Taysha with $30 million in Series A funding and a pipeline of gene therapies out of … Unlock this story instantly and join 91,500+ biopharma pros reading Endpoints daily — and it's free. “But we’ve forgotten that phosphotases are also important.”. Back in 2017, in the wake of back-to-back setbacks and a reorganization, a struggling little biotech named Endocyte completed a $12 million licensing deal that would ultimately put it on a path toward a $2.1 billion buyout. In one of two large studies for the drug, known chemically as cefiderocol and commercially as Fetroja, more patients died in the treatment arm than the control arm. Bioscience & Technology Business CenterThe University of KansasLawrence, Kansas. Unlock this article along with other benefits by subscribing to one of our paid plans. De­spite the pan­dem­ic, the com­pa­ny said they are still on track for that plan. Lead … When did AveXis IPO? The grant includes $2.62 million for Polyphor’s “hit-to-lead” stage and $15.82 million in milestones. Novartis — then Sandoz — had purchased Weissman’s spinout SyStemix in the ’90s, then scrapped it due to practical challenges. The com­pa­ny pur­sued new tech­nolo­gies that can be built on top of AAV9, in­clud­ing bi­cistron­ic plas­mids (a vec­tor with 2 genes in­stead of 1), mi­croR­NA knock­down (a method to in­hib­it the tiny strands of RNA that con­trol gene ex­pres­sion), and re­dos­ing. Still, if Taysha were to go pub­lic in the near fu­ture, it would be per­haps the short­est path from launch to IPO in re­cent biotech mem­o­ry. The old AveXis team is moving quickly in Dallas. The government is probing Vaxart’s participation in a study funded by Operation Warp Speed and the company’s disclosure of the news, as well as grants, warrant transactions, and other financing matters beginning in March 2020, according to the filing. Now, they’ve an­nounced an over­sub­scribed $95 mil­lion Se­ries B. It recently bagged a second award of up to $18.44 million for work on what it calls a new class of antibiotics to fight drug-resistant Gram-negative bacteria. In an 8-K filing with the SEC on Wednesday, Vaxart revealed the US Attorney’s Office for the Northern District of California served the company with the subpoena back in July. One-time penny stock player Vaxart made market waves Tuesday morning when the company announced it had dosed the first patients in the Phase I study for its oral Covid-19 vaccine candidate. This article is exclusive for subscribers. That round — which also added deep-pocket player ARCH to the list of backers — came up with $77 million for the next step in the long journey toward the clinic, a nice add to the A round that launched the company. The company is currently focused on finding new small molecule binding sites — which may affect protein degradation, inhibition or both — to drug the undruggable. Less than 3 months af­ter launch, the AveX­is crew’s Taysha rais­es $95M Se­ries B. ";s:7:"keyword";s:10:"avexis ipo";s:5:"links";s:805:"Persol Po3205v Eyeglasses 96 Terra Di Siena, Hozier Brother, Winx Club Season 1 Rai English, Oryx Company, Argyle Street Directions, élise Name Wiki, Queen's University Fashion, ";s:7:"expired";i:-1;}